Verastem Inc - Asset Resilience Ratio
Verastem Inc (VSTM) has an Asset Resilience Ratio of 7.08% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Also explore balance sheet size of Verastem Inc for the complete picture of this company's asset base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2025)
This chart shows how Verastem Inc's Asset Resilience Ratio has changed over time. See VSTM net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Verastem Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Verastem Inc (VSTM) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $16.13 Million | 7.08% |
| Total Liquid Assets | $16.13 Million | 7.08% |
Asset Resilience Insights
- Limited Liquidity: Verastem Inc maintains only 7.08% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Verastem Inc Industry Peers by Asset Resilience Ratio
Compare Verastem Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.11% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
|
Hyundai Bioscience Co. Ltd
KQ:048410 |
Biotechnology | 13.57% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 82.25% |
|
Lifecome Biochemistry Co Ltd
SHE:002868 |
Biotechnology | 4.69% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
Annual Asset Resilience Ratio for Verastem Inc (2011–2025)
The table below shows the annual Asset Resilience Ratio data for Verastem Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 3.58% | $8.81 Million | $246.44 Million | -- |
| 2024-12-31 | 0.00% | $0.00 | $101.54 Million | -- |
| 2023-12-31 | 39.55% | $59.22 Million | $149.72 Million | +25.92pp |
| 2022-12-31 | 13.64% | $12.96 Million | $95.05 Million | -59.07pp |
| 2021-12-31 | 72.71% | $79.00 Million | $108.66 Million | +25.12pp |
| 2020-12-31 | 47.58% | $73.44 Million | $154.35 Million | +25.53pp |
| 2019-12-31 | 22.06% | $31.99 Million | $145.05 Million | -21.15pp |
| 2018-12-31 | 43.21% | $119.79 Million | $277.24 Million | +38.20pp |
| 2017-12-31 | 5.01% | $4.50 Million | $89.79 Million | -53.04pp |
| 2016-12-31 | 58.05% | $48.55 Million | $83.63 Million | -17.45pp |
| 2015-12-31 | 75.50% | $85.39 Million | $113.09 Million | +15.92pp |
| 2014-12-31 | 59.58% | $58.77 Million | $98.65 Million | -6.22pp |
| 2013-12-31 | 65.80% | $82.42 Million | $125.26 Million | +15.78pp |
| 2012-12-31 | 50.02% | $46.48 Million | $92.92 Million | +4.53pp |
| 2011-12-31 | 45.49% | $26.86 Million | $59.04 Million | -- |
About Verastem Inc
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAP… Read more